

Perioperative Dextromethorphan as an Adjunct for Postoperative Pain

A Meta-analysis of Randomized Controlled Trials

Michael R. King, M.D., Karim S. Ladha, M.D., M.Sc., Amanda M. Gelineau, M.D.,
T. Anthony Anderson, Ph.D., M.D.



This article has been selected for the ANESTHESIOLOGY CME Program. Learning objectives and disclosure and ordering information can be found in the CME section at the front of this issue.

ABSTRACT

Background: *N*-methyl-D-aspartate receptor antagonists have been shown to reduce perioperative pain and opioid use. The authors performed a meta-analysis to determine whether the use of perioperative dextromethorphan lowers opioid consumption or pain scores.

Methods: PubMed, Web of Science, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Pubget, and EMBASE were searched. Studies were included if they were randomized, double-blinded, placebo-controlled trials written in English, and performed on patients 12 yr or older. For comparison of opioid use, included studies tracked total consumption of IV or intramuscular opioids over 24 to 48 h. Pain score comparisons were performed at 1, 4 to 6, and 24 h postoperatively. Difference in means (MD) was used for effect size.

Results: Forty studies were identified and 21 were eligible for one or more comparisons. In 848 patients from 14 trials, opioid consumption favored dextromethorphan (MD, -10.51 mg IV morphine equivalents; 95% CI, -16.48 to -4.53 mg; $P = 0.0006$). In 884 patients from 13 trials, pain at 1 h favored dextromethorphan (MD, -1.60; 95% CI, -1.89 to -1.31; $P < 0.00001$). In 950 patients from 13 trials, pain at 4 to 6 h favored dextromethorphan (MD, -0.89; 95% CI, -1.11 to -0.66; $P < 0.00001$). In 797 patients from 12 trials, pain at 24 h favored dextromethorphan (MD, -0.92; 95% CI, -1.24 to -0.60; $P < 0.00001$).

Conclusion: This meta-analysis suggests that dextromethorphan use perioperatively reduces the postoperative opioid consumption at 24 to 48 h and pain scores at 1, 4 to 6, and 24 h. (ANESTHESIOLOGY 2016; 124:696-705)

NMETHYL-D-ASPARTATE (NMDA) receptor antagonists have become widely used adjuncts for postoperative analgesia.^{1,2} Ketamine, a well-studied NMDA antagonist, has been shown to decrease postoperative pain when administered preemptively,^{3,4} intraoperatively,⁵ and postoperatively,^{6,7} without causing an increase in sedation but with a notable increase in hallucinations and nightmares.⁸ Dextromethorphan, an NMDA receptor antagonist that is most routinely used as an oral antitussive, has also been extensively studied for its use as a perioperative analgesic adjunct.⁹⁻²⁹ Dextromethorphan has previously undergone systematic review without quantitative meta-analysis in which the authors determined that the drug was a potentially useful analgesic adjunct, but there still remained significant questions about the consistency of findings between studies.³⁰ Since that systematic review was accepted for publication in 2005, there have been more than 10 additional studies^{9-14,31-34} on dextromethorphan for postoperative pain control. A meta-analysis

What We Already Know about This Topic

- Some *N*-methyl-D-aspartate receptor antagonists reduce postoperative pain and opioid requirements
- Dextromethorphan, a low-affinity noncompetitive *N*-methyl-D-aspartate receptor antagonist, may be beneficial in the perioperative setting

What This Article Tells Us That Is New

- This meta-analysis identified 21 studies describing the effects of dextromethorphan on postoperative pain and opioid consumption
- Dextromethorphan was found to reduce pain from 1 to 24 h postoperatively and was found to reduce morphine requirements 24 to 48 h after surgery

of the results of studies that investigate dextromethorphan for its effect on postoperative pain and opioid reduction has not yet been published. Therefore, we performed a meta-analysis on the use of preoperative dextromethorphan and its effects on opioid consumption and postoperative pain scores.

Submitted for publication May 28, 2015. Accepted for publication October 14, 2015. From the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts. Current affiliation: Department of Anesthesia, Toronto General Hospital and the University of Toronto, Toronto, Ontario, Canada (K.S.L.).

Copyright © 2015, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. All Rights Reserved. Anesthesiology 2016; 124:696-705

Materials and Methods

This study is a meta-analysis of existing, publicly available literature, did not involve the collection of new human or animal data, and is exempt from the institutional review board review. The Cochrane specifications for systematic reviews was used to guide the construction of this meta-analysis.³⁵ A systematic search was performed in PubMed, Web of Science, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Pubget, and EMBASE on August 4, 2014. The following search terms were used: (dextromethorphan) AND acute pain; (dextromethorphan) AND postoperative pain; (dextromethorphan) AND pain. Trials were only included if they were randomized, double-blinded, placebo-controlled, and published in English. Unpublished abstracts and reports were excluded. Pediatric trials on patients less than 12 yr of age were also excluded. Authors of the trials were not contacted for original data.

To ensure the quality of included trials, each trial was scored based on a modified validated scale previously used for meta-analysis.³⁶ The scale was designed to evaluate the quality of placebo-controlled, randomized trials and includes the following parameters:

1. Randomization: a point was given for stating the trial was randomized. An additional point was given if randomization was described and appropriate, such as the use of a random number generator.
2. Blinding: a point was given if the trial was stated to be double-blind. If blinding method was described and appropriate, such as the use of identical placebo pills, an additional point was given.
3. Withdrawals: a point was given if patient withdrawals and the reasons for withdrawals were reported.
4. Pain intensity: to ensure that the trial evaluated clinically significant pain, a point was given if mean visual analog pain scores were greater than 30 mm or greater than 3 of 10 on a numeric rating scale.
5. Power analysis: a point was given if sample size was determined through the use of a power analysis.

Thus, the minimum requirements for inclusion would be a score of 2 points and the maximum score would be 7 points.

To be included in the meta-analyses, we required all trials to have a treatment arm in which IV, intramuscular, or *per os* dextromethorphan was administered before surgery—if treatment groups also received intraoperative or postoperative doses of dextromethorphan (table 1), they were included as well. Only test groups from studies in which dextromethorphan was administered preoperatively were included for analysis. If test groups were administered dextromethorphan only intraoperatively or postoperatively, they were not included for analysis. If multiple dextromethorphan dosages were administered in an included study, the highest dose group was used for the comparison. However, as a sensitivity analysis, all comparisons were recalculated, where possible, using the lowest dose groups.

The outcome variables we sought were postoperative opioid consumption, pain scores, and incidence of side effects. The investigation of published studies led to the *a posteriori* selection for analysis of total opioid consumption for 24 to 48 h postoperatively, numeric pain scores at 1, 4 to 6, and 24 h, and the incidence of opioid- and dextromethorphan-related side effects. For comparison of postoperative opioid use, studies were included if they tracked total use of opioids over a 24- or 48-h period. If an opioid other than IV morphine was used, such as meperidine, the reported values were converted into IV morphine equivalents using an online calculator.³⁷ Inclusion required sole use of opioids as a *pro re nata* analgesic. Comparisons between groups that received the same nonopioid intervention (such as a single dose of a nonsteroidal antiinflammatory drug [NSAID] in both control and dextromethorphan groups) were also included.

Studies were eligible for pain score comparisons if they reported pain scores on a standardized 0 to 10 numeric rating scale, such as the visual analog scale. Numeric pain score comparisons were performed at three time points: 1, 4 to 6, and 24 h postoperatively. For the 1-h group, studies were included if they reported pain scores within 1 h postoperatively. Thus, studies were also included in this group if they did not report pain scores at 1 h but did report in the first hour in the postanesthetic care unit. For the 4- to 6-h group, studies were included if they reported pain scores at 4 or 6 h. If a study reported pain scores at both times, the score at 4 h was used.

We intended to compare the incidence of opioid-related side effects, such as nausea and itching, as well as dextromethorphan-related side effects, such as nausea and euphoria, but this was not feasible due to the small number of events reported. Thus, rather than report meta-analysis of side effects, we systematically reviewed the included trials for reported side effects.

Statistical analyses were performed with Review Manager version 5.3 (The Nordic Cochrane Centre, Denmark). All calculations required knowledge of the mean and SD for the compared parameters. Some studies represented mean and SD graphically—in these cases, the computer program Plot Digitalizer³⁸ was used to estimate the values at the set time points. As mean and SD were used for comparison calculation, the effect size is expressed as difference in means (MD). By convention, MDs favoring dextromethorphan were considered negative and those favoring control considered positive. To account for anticipated heterogeneity, a random-effects model³⁹ was used for all calculations. We also used the I^2 statistic to assess the degree to which differences between trials were due to heterogeneity.⁴⁰ Alpha was set at 0.05 and, after performing a Bonferroni correction accounting for four total comparisons, the significance criterion set at 0.0125. All comparisons are presented graphically in this article by using forest plots.⁴¹

Table 1. List of Studies Included in One or More of the Comparisons in the Meta-analysis

Studies	Quality Score	Dextromethorphan Patients	Control Patients	Dextromethorphan Dosing	Dextromethorphan Dose Timing
Entezary <i>et al.</i> ⁹	3	54	58	1 mg/kg PO	Night before surgery
Suski <i>et al.</i> ¹⁰	6	30	30	30 or 45 mg PO (weight based) ×4	1 h preoperatively and at 8, 20, and 32 h postoperatively
Mahmoodzadeh <i>et al.</i> ¹¹	6	23 (in 45 group), 24 (in 90 group)	22	45 or 90 mg PO	2 h preoperatively
Chau-In <i>et al.</i> ¹²	7	50	48	30 mg PO ×4	60 min preoperatively and three doses over first 24 h postoperatively
Lu <i>et al.</i> ¹³	6	20 DM, 20 DM + ketorolac	20 control, 20 ketorolac	40 mg IM	30 min preoperatively
Yeh <i>et al.</i> ¹⁴	4	30 DM plus epidural	30 GA plus epidural; 30 GA only	40 mg IM	30 min preoperatively
Wu <i>et al.</i> ¹⁵	5	25 DM 25 DM + lidocaine IV	25 control, 25 lidocaine IV	40 mg IM	30 min preoperatively
Yeh <i>et al.</i> ¹⁶	5	20 DM, 20 DM + tenoxicam	22 control, 21 tenoxicam	40 mg IM	30 min preoperatively
Weinbroum <i>et al.</i> ¹⁷	7	29 DM + PCA 28 DM + PCEA	27 PCA 29 PCEA	90 mg PO	90 min preoperatively
Weinbroum <i>et al.</i> ¹⁸	6	29	27	90 mg PO ×3	90 min preoperatively and on POD 1 and 2
Weinbroum <i>et al.</i> ¹⁹	6	25 (in 60 group), 23 (in 90 group)	24	60 or 90 mg PO ×3	90 min preoperatively and on POD 1 and 2
Weinbroum ²⁰	6	18 DM + epidural, 20 DM + GA	17 epidural, 20 GA	90 mg PO	90 min preoperatively
Weinbroum <i>et al.</i> ²¹	6	16 (in 60 group), 17 (in 90 group)	20	60 or 90 mg PO	90 min preoperatively
Helmy and Bali ²²	5	20 (preoperatively), 20 (postoperatively)	20	120 mg IM	30 min before incision or 30 min before end of surgery
Wadhwa <i>et al.</i> ²³	7	22	34	200 mg PO ×3	120 min preoperatively and 8 and 16 h postoperatively
Liu <i>et al.</i> ²⁴	3	30	30	40 mg IM	30 min preoperatively
Wu <i>et al.</i> ²⁵	3	15 (in 10 group), 15 (in 20 group), 15 (in 40 group)	15	10, 20, or 40 mg IM	30 min preoperatively
Wong <i>et al.</i> ²⁶	3	30	30	40 mg IM	30 min preoperatively
Wu <i>et al.</i> ²⁷	2	30 (given preoperatively) 30 (given intraoperatively)	30	40 mg IM	Just before incision or intraoperatively
Grace <i>et al.</i> ²⁸	5	18	19	60 mg PO ×2	Night before and 1 h preoperatively
Kawamata <i>et al.</i> ²⁹	5	12 (in 30 group), 12 (in 45 group)	12	30 or 45 mg PO	60 min preoperatively

DM = dextromethorphan; GA = general anesthesia; IM = intramuscular; NCA = nurse-controlled analgesia (doses dependent on patient request and nurse administration on a PRN schedule); PACU = postanesthesia care unit; PCA = patient-controlled analgesia; PCEA = patient-controlled epidural analgesia; PO = *per os*; POD = postoperative day; PRN = *pro re nata* (as needed).

Results

Study Selection

The selection process is summarized in figure 1. Table 1 lists all studies used in the comparisons including pertinent aspects of

their design and subgroups. A total of 40 studies were identified and a total of 19 were excluded, leaving 21 studies that were used in at least one comparison. The median quality score of these studies was 5 of 7 with an interquartile range of 2.

Surgery Type	Anesthesia Type	Comparisons Tracked	PRN Analgesic Tracked	Tracked Side Effects	Comments
Knee arthroscopy	Spinal	Pain 1 and 4 h, total opioid 24 h	Morphine NCA	Yes	
Scoliosis repair	General	Pain 1, 4–6, 24 h, total opioid 24 h	Morphine IV NCA	Yes	
Open cholecystectomy	General	Pain 1, 6, and 24 h, total opioid 24 h	Morphine IV NCA	No	Used 90 mg group for comparison
Total abdominal hysterectomy	General	Pain 1, 6, and 24 h, total opioid 24 h	Morphine IV PCA	No	
Vaginal hysterectomy	General	Pain 1, 4, and 24 h	Morphine IV PCA	Yes	Performed ketorolac and nonketorolac comparisons
Colon surgery	General + epidural	Pain 1, 4, and 24 h	0.2% ropivacaine and 0.1 mg/ml morphine PCEA	Yes	Excluded GA only group as no direct DM comparison
Laparoscopic cholecystectomy	General	Pain 1, 4, and 24 h, total opioid 48 h	Meperidine IM NCA	Yes	Performed lidocaine and nonlidocaine comparisons
Laparoscopic cholecystectomy	General	Pain 1, 4, and 24 h, total opioid 48 h	Meperidine IM NCA	Yes	Performed tenoxicam and nontenoxicam comparisons
Bone tumor resection	General or general + epidural	Pain 6 and 24 h	PCEA (ropivacaine 3.2 mg plus fentanyl 8 µg/dose) or PCA (morphine 2 mg/dose) only in PACU, then diclofenac	Yes	PCA only used in PACU so no 24-h opioid comparison
Bone tumor resection	General + epidural	Pain 1, 6, and 24 h	PCEA (1.6 mg ropivacaine plus 4 µg/ml fentanyl) continuous and by demand	Yes	
Bone tumor resection	General	Pain 1 and 24 h, total opioid 24 h	Morphine IV PCA	Yes	Used 90 mg group for comparison
Hernia repair or knee arthroscopy	General or epidural	Pain 1 and 4–6 h	Morphine IV PCA for 2 h then diclofenac	Yes	Compared both epidural and GA groups
Hernia repair or knee arthroscopy	Epidural	Pain 1 and 6 h	Morphine IV PCA in PACU and diclofenac at home	Yes	Used 90 mg group for comparisons as this was used in all the group's further studies
Upper abdominal surgery	General	Total opioid 24 h	Meperidine IV PCA	Yes	Excluded postgroup
Knee replacement or reconstruction	General	Total opioid 24 h	Morphine IV PCA	Yes	
Hemorrhoidectomy	Local	Total opioid 48 h	Meperidine IM NCA	Yes	
Upper abdominal surgery	General	Pain 1, 4, and 24 h, total opioid 24 h	Morphine IV PCA	Yes	Used 40 mg group for comparison as this was used in all the group's further studies
Modified radical mastectomy	General	Total opioid 48 h	Meperidine IM NCA	Yes	
Laparoscopic cholecystectomy	General	Total opioid 48 h	Meperidine IM NCA	Yes	Excluded intraoperative group
Laparotomy	General	Total opioid 48 h	Morphine IV PCA	No	
Tonsillectomy	General	Pain 24 h	Diclofenac PO at home	Yes	Used 45 mg group for comparison

Total Opioid Consumption

A total of 14 trials reported mean and SD of opioid consumption for the first 24 or 48 h postoperatively and a total of 848 patients were included in the comparison.

MD favored dextromethorphan (MD, -10.51 mg of IV morphine equivalents; 95% CI, -16.48 to -4.53 mg; $P = 0.0006$; fig. 2). Three studies in particular, reported by Weinbroum *et al.*,¹⁹ Helmy and Bali,²² and Wu




Fig. 1. Diagram of study selection for each comparison. Note that exclusions on the comparison level, such as exclusion for not reporting mean and SD for the specific comparison, are not shown.




Fig. 2. Forest plot for total opioid use over 24 or 48h. The table displays the study with reference number, mean, SD, sample size, difference in means in milligrams of IV morphine with 95% CI, heterogeneity, overall effect, and *P* values. The forest plot displays point estimate and 95% CI.

*et al.*²⁵ were statistical outliers with an MD of less than -20. To ensure that these three studies alone had not resulted in the comparison's significance, a sensitivity analysis was performed with them excluded. The overall effect was lessened, but the comparison remained significant (MD, -4.45 mg IV morphine equivalents; 95% CI, -7.47 to -1.43 mg; *P* = 0.004) and *I*², although still high, was reduced from 97 to 88%.

Pain Scores at 1, 4 to 6, and 24 h

Pain scores at 1 h were reported as mean and SD in 13 studies with a total of 884 included patients. MD favored dextromethorphan (-1.60; 95% CI, -1.89 to -1.31; *P* < 0.00001; fig. 3). Weinbroum *et al.*¹⁹ was an outlier with an MD of less than -4. After exclusion, the overall effect was lessened, but the comparison remained significant (-1.50; 95% CI, -1.78 to -1.22; *P* < 0.00001) and *I*² decreased from 91 to 90%.

Pain scores at 4 to 6 h were reported in 13 studies with a total of 950 included patients. Three subgroups in two studies (reported by Suski *et al.*¹⁰ and Weinbroum²⁰) reported pain scores at both 4 and 6 h and the values recorded at the 4 h were used in the comparison. MD favored dextromethorphan (-0.89; 95% CI, -1.11 to -0.66; *P* < 0.00001; fig. 4) with an *I*² of 88%.

Pain scores at 24 h were reported in 12 studies with 797 included patients. Dextromethorphan was also favored at this time point (MD, -0.92; 95% CI, -1.24 to -0.60; *P* < 0.00001; fig. 5) with an *I*² of 92%.

Comparisons Using Lower-dose Dextromethorphan Groups

A total of three studies in the opioid consumption, 24-h pain score, and 1-h pain score comparisons and two studies in the 4- to 6-h pain score comparison included multiple dosing regimens




Fig. 3. Forest plot for comparison of pain scores at 1 h postoperatively. The table displays the study with reference number, mean, SD, sample size, difference in means of visual analog scale with 95% CI, heterogeneity, overall effect, and P values. The forest plot displays point estimate and 95% CI. PCA = patient-controlled analgesia; PCEA = patient-controlled epidural analgesia.




Fig. 4. Forest plot for comparison of pain scores at 4 to 6 h postoperatively. The table displays the study with reference number, mean, SD, sample size, difference in means with 95% CI, heterogeneity, overall effect, and P values. The forest plot displays point estimate and 95% CI. PCA = patient-controlled analgesia; PCEA = patient-controlled epidural analgesia.

of dextromethorphan. Of note, two of these studies (reported by Wu *et al.*²⁵ and Weinbroum *et al.*²¹) were completed by groups that only used their highest dose in subsequent studies—thus, their highest dosing groups best approximated the most common dextromethorphan doses in the study and were used for the initial comparisons. When comparisons were recalculated using the low-dose instead of high-dose groups for comparison, all results remained significant although with a lower magnitude of effect (opioid consumption MD, -10.05 mg of IV morphine equivalents; 95% CI, -15.79 to -4.31 mg, $P = 0.0006$; pain at 1 h: MD, -1.50; 95% CI, -1.79 to -1.21, $P < 0.00001$; pain at 4 to 6 h: MD, -0.87; 95% CI, -1.11 to -0.64, $P < 0.00001$; and pain at 24 h: MD, -0.65; 95% CI, -0.95 to -0.35; $P < 0.0001$).

Incidence of Side Effects

Eighteen of 21 trials included in our meta-analyses tracked the incidence of side effects, which for both opioids and dextromethorphan primarily consist of nausea, vomiting, dizziness, and lightheadedness. Ten studies reported either no side effects or a nonsignificant difference between groups.^{9,10,13,14,16,19,20,22,24,27,29} Five studies did, however, report a decrease in side effects in groups receiving dextromethorphan.^{15,17,18,25,26} One study²³ found a higher incidence of nausea in the dextromethorphan group, with rating mild-to-moderate nausea reported by patients at 31 time points in the dextromethorphan group compared with 20 time points in the control group although no patients reported severe nausea at any time. Weinbroum




Fig. 5. Forest plot for comparison of pain scores at 24 h postoperatively. The table displays the study with reference number, mean, SD, sample size, difference in means with 95% CI, heterogeneity, overall effect, and *P* values. The forest plot displays point estimate and 95% CI. PCA = patient-controlled analgesia; PCEA = patient-controlled epidural analgesia.

*et al.*²¹ tracked sedation using a standardized scale and found an increase in sedation in the placebo group.

Discussion

A variety of study designs in multiple hospital settings and countries have attempted to elucidate the value of perioperative dextromethorphan as an adjunctive analgesic. In a prior report, these efforts were synthesized in a qualitative systematic review of NMDA receptor antagonists' role in decreasing postoperative pain and opioid consumption, which demonstrated a significant benefit from dextromethorphan in 67% of included studies.² In addition, a separate qualitative systematic review of dextromethorphan that shared in common 15 of the studies used in this analysis suggested that dextromethorphan had potential as an adjunct to postoperative opioid analgesics but did note variability among the analyzed studies.³⁰ Here, we have systematically searched the published literature on the preoperative use of dextromethorphan to decrease postoperative pain and opioid use. Ultimately, we identified 21 trials published between 1998 and 2013 that addressed these metrics and were suitable for quantitative meta-analysis. The results of our meta-analyses suggest that, when used preoperatively, dextromethorphan significantly decreases pain and opioid use in the postoperative period.

To objectively index included trials by design quality, we scored each trial based on a quality index. The majority of studies in our meta-analyses scored in the 5 to 7 range. These studies demonstrated a high degree of transparency in their study designs and sampling processes. A minority of studies scored in the 2 to 4 range, with a score of 2 representing the minimum requirements of being a randomized blinded trial. Although we did not weigh trials based on their scores, the average scores of the trials do reflect the average high quality of the studies from which we draw our conclusions.

As an NMDA receptor antagonist,⁴² dextromethorphan has been proposed to exert its effects as a preemptive analgesic by preventing NMDA-mediated calcium current and subsequent modulation of nociception in spinal pain fibers and the central nervous system. This in turn prevents a pain phenomenon known as "windup" that results in amplified subsequent responses to painful stimuli and poorer responses to opioids.^{43–46} In previous trials, dextromethorphan has shown benefit in various chronic pain conditions including diabetic neuropathy, postherpetic neuralgia,⁴⁷ and phantom limb pain.^{48,49} Effects on cancer pain have also been investigated in at least two trials with mixed results.^{50,51}

Multimodal preemptive analgesic adjuncts, including NMDA receptor antagonists, local anesthetic infiltration, NSAIDs, epidural analgesia, and preemptive opioids, have been the subject of a prior meta-analysis.³⁶ This study found benefit with preemptive NSAIDs, epidural analgesia, and local anesthetic infiltration, but its comparisons for both ketamine and dextromethorphan were equivocal. In contrast, the same year, a meta-analysis of perioperative IV ketamine use reported a mean of 15.7 mg less morphine consumption at 24 h and mean pain score improvements of 0.89 at 6 h, 0.42 at 12 h, 0.35 at 24 h, and 0.27 at 48 h.⁵² These results are remarkably similar to our own. A more recent meta-analysis of perioperative IV ketamine found benefits for opioid consumption and time to first analgesic but did note increased hallucinations and nightmares.⁸ The statistic used for this analysis was the standardized mean difference rather than mean difference, making direct comparison to effect observed in our own study difficult.

However, although ketamine is widely used as a multimodal adjunct worldwide, our anecdotal experience from multiple institutions is that dextromethorphan does not appear to share the same level of popularity and is very rarely used as an adjunct for postoperative analgesia. On the basis of our findings, the use of dextromethorphan

perioperatively could potentially provide similar benefits to preemptive ketamine therapy in a simple oral, intramuscular, or IV formulation. Further investigation, particularly a head-to-head randomized trial alongside placebo, may help clarify whether the different NMDA antagonists provide similar levels of relief with a similar incidence of dysphoric or other side effects, or not. Additional research may also explore whether there is benefit from the simultaneous use of more than one NMDA receptor antagonist as it is unclear whether this would result in an additive, synergistic, or antagonistic effect.

Well-documented dextromethorphan side effects and concerns include dose-related tachycardia, respiratory depression, gastrointestinal symptoms, and abuse potential.⁵³ Although its recreational abuse potential is clear, dextromethorphan dependence has only been rarely described,^{54,55} and its abuse is best described in adolescents.^{56,57} Recent work has described dose-dependent hallucinogenic properties of dextromethorphan as well as acute changes in memory and cognition^{58,59} although these effects typically occurred at doses well in excess of those used in the included studies. Thus, it seems reasonable to avoid doses above 2 mg/kg *per os*, which has been described as a dose above which dissociative effects are typically seen,⁶⁰ in order to prevent neurologic disturbances before surgery. However, there exists, to our knowledge, no evidence that a single dose of dextromethorphan for preemptive analgesia would increase potential for postoperative abuse, and indeed, review of the included trials revealed a minimal incidence of dextromethorphan-related adverse effects.

Although opioids are a mainstay of effective perioperative analgesia, their use is nonetheless frequently associated with side effects that can increase hospital costs and length of stay.⁶¹ Multimodal analgesia has been proposed as a way to improve pain control while reducing side effects,⁶² but to date, little evidence exists to link opioid-sparing analgesic regimens to reduced opioid-related adverse effects. The available studies were insufficient for meta-analysis on the incidence of side effects with dextromethorphan, but our qualitative review of the literature suggests that most studies saw minimal change in the incidence of side effects. Ketamine, in contrast, was shown in prior meta-analysis to increase the risk of hallucinations when administered in awake patients although the incidence of opioid-related side effects was also unchanged.⁵² This difference highlights the fact that different NMDA receptor antagonists are not necessarily interchangeable, and therefore, continued exploration into other agents such as dextromethorphan and memantine is still warranted. Larger studies may clarify whether opioid-sparing doses of dextromethorphan are able to quantitatively decrease the incidence of opioid-related side effects without causing hallucinations at similar rates to ketamine.

Similar to the systematic review by Duedahl *et al.*,³⁰ we observed a high degree of heterogeneity, with an I^2 greater than 80% in each comparison. This is likely a reflection of the variability between study designs, such as differences in type of surgery, dextromethorphan dosing regimens, dextromethorphan

administration routes, and postoperative analgesic regimens. We had anticipated this and therefore used a random-effects model for all of our calculations. The high heterogeneity does, nonetheless, demonstrate the variability in findings among dextromethorphan studies and highlights the need for a larger study with a standardized protocol to clarify dextromethorphan's role in the perioperative setting. Important details to clarify include the optimal perioperative dextromethorphan dose and duration of use, the incidence of side effects, and whether or not the perioperative use of dextromethorphan improves outcomes such as hospital length of stay.

Our analysis is also limited by the fundamental reliance of meta-analyses on the existing data and the reporting mechanisms of the original studies. Many high-quality studies needed to be excluded from the quantitative analyses due to reporting results in forms other than mean and SD, tracking opioid use over periods less than 24 h, or reporting pain scores in forms other than fixed intervals (such as only reporting the worst recorded). In a small number of studies with multiple dextromethorphan dosing arms, we also had to exclude groups in order to avoid duplicating control patients in our comparisons. As a result, our quantitative analyses do not necessarily represent the full body of literature on the perioperative use of dextromethorphan. In addition, due to the heterogeneity of published studies, this is an *a posteriori*-derived analysis of total opioid consumption for 24 to 48 h postoperatively and pain scores at 0 to 1 h, 4 to 6 h, and 24 h postoperatively.

Despite these limitations, our comparisons do nonetheless represent a cross-section of several hundred patients in the available randomized controlled trials on the effects of preoperative dextromethorphan on postoperative pain control with significantly favorable results. To date, no large randomized controlled trial has been conducted on this topic. Our quantitative meta-analyses of the existing randomized controlled studies of dextromethorphan for postoperative pain control demonstrated a significant reduction in postoperative opioid use for 24 to 48 h after surgery as well as pain represented by pain scores up to 24 h after surgery. Due to high heterogeneity between the existing trials and the lack of a single large randomized study on this topic, further evidence is required to definitively determine a benefit.

Acknowledgments

The authors thank Hang Lee, Ph.D. (Harvard Medical School and the Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts), for statistical consultation.

This work was conducted with support from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources and National Center for Advancing Translational Sciences, National Institutes of Health [Bethesda, Maryland] Award UL1 TR001102) and financial contributions from Harvard University (Cambridge, Massachusetts) and its affiliated academic healthcare centers.

Competing Interests

The authors declare no competing interests.

Correspondence

Address correspondence to Dr. Anderson: Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street GRJ 409, Boston, Massachusetts 02114. tanderson9@mgh.harvard.edu. This article may be accessed for personal use at no charge through the Journal Web site, www.anesthesiology.org.

References

1. Suzuki M: Role of *N*-methyl-D-aspartate receptor antagonists in postoperative pain management. *Curr Opin Anaesthesiol* 2009; 22:618–22
2. McCartney CJ, Sinha A, Katz J: A qualitative systematic review of the role of *N*-methyl-D-aspartate receptor antagonists in preventive analgesia. *Anesth Analg* 2004; 98:1385–400
3. Roytblat L, Korotkoruchko A, Katz J, Glazer M, Greemberg L, Fisher A: Postoperative pain: The effect of low-dose ketamine in addition to general anesthesia. *Anesth Analg* 1993; 77:1161–5
4. Launo C, Bassi C, Spagnolo L, Badano S, Ricci C, Lizzi A, Molinino M: Preemptive ketamine during general anesthesia for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. *Minerva Anestesiol* 2004; 70:727–34; 734–8
5. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK, Beach ML: Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. *ANESTHESIOLOGY* 2010; 113:639–46
6. Adriaenssens G, Vermeyen KM, Hoffmann VL, Mertens E, Adriaensen HF: Postoperative analgesia with i.v. patient-controlled morphine: Effect of adding ketamine. *Br J Anaesth* 1999; 83:393–6
7. Zakine J, Samarcq D, Lorne E, Moubarak M, Montravers P, Beloucif S, Dupont H: Postoperative ketamine administration decreases morphine consumption in major abdominal surgery: A prospective, randomized, double-blind, controlled study. *Anesth Analg* 2008; 106:1856–61
8. Laskowski K, Stirling A, McKay WP, Lim HJ: A systematic review of intravenous ketamine for postoperative analgesia. *Can J Anaesth* 2011; 58:911–23
9. Entezary SR, Farshadpour S, Alebouyeh MR, Imani F, Emami Meybodi MK, Yari beygi H: Effects of preoperative use of oral dextromethorphan on postoperative need for analgesics in patients with knee arthroscopy. *Anesth Pain Med* 2014; 4:e11187
10. Suski M, Bujak-Gizycka B, Madej J, Kacka K, Dobrogowski J, Woron J, Olszanecki R, Korbut R: Co-administration of dextromethorphan and morphine: Reduction of post-operative pain and lack of influence on morphine metabolism. *Basic Clin Pharmacol Toxicol* 2010; 107:680–4
11. Mahmoodzadeh H, Movafegh A, Beigi NM: Preoperative oral dextromethorphan does not reduce pain or morphine consumption after open cholecystectomy. *Middle East J Anaesthesiol* 2010; 20:559–63
12. Chau-In W, Sukmuan B, Ngamsangsirisapt K, Jirareungsak W: Efficacy of pre- and postoperative oral dextromethorphan for reduction of intra- and 24-hour postoperative morphine consumption for transabdominal hysterectomy. *Pain Med* 2007; 8:462–7
13. Lu CH, Liu JY, Lee MS, Borel CO, Yeh CC, Wong CS, Wu CT: Preoperative cotreatment with dextromethorphan and ketorolac provides an enhancement of pain relief after laparoscopic-assisted vaginal hysterectomy. *Clin J Pain* 2006; 22:799–804
14. Yeh CC, Jao SW, Huh BK, Wong CS, Yang CP, White WD, Wu CT: Preincisional dextromethorphan combined with thoracic epidural anesthesia and analgesia improves postoperative pain and bowel function in patients undergoing colonic surgery. *Anesth Analg* 2005; 100:1384–9
15. Wu CT, Borel CO, Lee MS, Yu JC, Liou HS, Yi HD, Yang CP: The interaction effect of perioperative cotreatment with dextromethorphan and intravenous lidocaine on pain relief and recovery of bowel function after laparoscopic cholecystectomy. *Anesth Analg* 2005; 100:448–53
16. Yeh CC, Wu CT, Lee MS, Yu JC, Yang CP, Lu CH, Wong CS: Analgesic effects of preincisional administration of dextromethorphan and tenoxicam following laparoscopic cholecystectomy. *Acta Anaesthesiol Scand* 2004; 48:1049–53
17. Weinbroum AA, Bender B, Nirkin A, Chazan S, Meller I, Kollender Y: Dextromethorphan-associated epidural patient-controlled analgesia provides better pain- and analgesics-sparing effects than dextromethorphan-associated intravenous patient-controlled analgesia after bone-malignancy resection: A randomized, placebo-controlled, double-blind study. *Anesth Analg* 2004; 98:714–22
18. Weinbroum AA, Bender B, Bickels J, Nirkin A, Marouani N, Chazam S, Meller I, Kollender Y: Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement: A randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated patients. *Cancer* 2003; 97:2334–40
19. Weinbroum AA, Gorodetzky A, Nirkin A, Kollender Y, Bickels J, Marouani N, Rudick V, Meller I: Dextromethorphan for the reduction of immediate and late postoperative pain and morphine consumption in orthopedic oncology patients: A randomized, placebo-controlled, double-blind study. *Cancer* 2002; 95:1164–70
20. Weinbroum AA: Dextromethorphan reduces immediate and late postoperative analgesic requirements and improves patients' subjective scorings after epidural lidocaine and general anesthesia. *Anesth Analg* 2002; 94:1547–52
21. Weinbroum AA, Lalayev G, Yashar T, Ben-Abraham R, Niv D, Flaishon R: Combined pre-incisional oral dextromethorphan and epidural lidocaine for postoperative pain reduction and morphine sparing: A randomised double-blind study on day-surgery patients. *Anaesthesia* 2001; 56:616–22
22. Helmy SA, Bali A: The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. *Anesth Analg* 2001; 92:739–44
23. Wadhwa A, Clarke D, Goodchild CS, Young D: Large-dose oral dextromethorphan as an adjunct to patient-controlled analgesia with morphine after knee surgery. *Anesth Analg* 2001; 92:448–54
24. Liu ST, Wu CT, Yeh CC, Ho ST, Wong CS, Jao SW, Wu CC, Kang JC: Premedication with dextromethorphan provides posthemorrhoidectomy pain relief. *Dis Colon Rectum* 2000; 43:507–10
25. Wu CT, Yu JC, Liu ST, Yeh CC, Li CY, Wong CS: Preincisional dextromethorphan treatment for postoperative pain management after upper abdominal surgery. *World J Surg* 2000; 24:512–7
26. Wong CS, Wu CT, Yu JC, Yeh CC, Lee MM, Tao PL: Preincisional dextromethorphan decreases postoperative pain and opioid requirement after modified radical mastectomy. *Can J Anaesth* 1999; 46:1122–6
27. Wu CT, Yu JC, Yeh CC, Liu ST, Li CY, Ho ST, Wong CS: Preincisional dextromethorphan treatment decreases postoperative pain and opioid requirement after laparoscopic cholecystectomy. *Anesth Analg* 1999; 88:1331–4
28. Grace RF, Power I, Umedaly H, Zammit A, Mersiades M, Cousins MJ, Mather LE: Preoperative dextromethorphan reduces intraoperative but not postoperative morphine requirements after laparotomy. *Anesth Analg* 1998; 87:1135–8

29. Kawamata T, Omote K, Kawamata M, Namiki A: Premedication with oral dextromethorphan reduces postoperative pain after tonsillectomy. *Anesth Analg* 1998; 86:594–7
30. Duedahl TH, Rømsing J, Møiniche S, Dahl JB: A qualitative systematic review of peri-operative dextromethorphan in post-operative pain. *Acta Anaesthesiol Scand* 2006; 50:1–13
31. Ehret GB, Daali Y, Chabert J, Rebsamen M, Wolff A, Forster A, Moursli F, Fritschy D, Rossier MF, Piguet V, Dayer P, Gex-Fabry M, Desmeules JA: Influence of CYP2D6 activity on pre-emptive analgesia by the *N*-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain. *Pain Physician* 2013; 16:45–56
32. Abu-Samra MM, Ismaeil WA: Pre-emptive oral dextromethorphan reduces both postoperative and packing removal pain in patients undergoing nasal surgery. *Saudi Med J* 2009; 30:214–8
33. Ali SM, Shahrabano S, Ulhaq TS: Tramadol for pain relief in children undergoing adenotonsillectomy: A comparison with dextromethorphan. *Laryngoscope* 2008; 118:1547–9
34. Aoki T, Yamaguchi H, Naito H, Shiiki K, Ota Y, Kaneko A: Dextromethorphan premedication reduced postoperative analgesic consumption in patients after oral surgery. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 102:591–5
35. Higgins JPT, Green S: *Cochrane Handbook for Systematic Reviews of Interventions* 4.2.6 [updated September 2006]. Chichester, John Wiley & Sons, Ltd., 2006
36. Ong CK, Lirk P, Seymour RA, Jenkins BJ: The efficacy of pre-emptive analgesia for acute postoperative pain management: A meta-analysis. *Anesth Analg* 2005; 100:757–73
37. Opioid converter, opioid conversions, pain management. Available at: <http://www.globalrph.com/narcoticonv.htm>. Accessed May 20, 2015
38. Plot Digitalizer. Available at: <http://plotdigitizer.sourceforge.net>. Accessed July 20, 2015
39. Brockwell SE, Gordon IR: A comparison of statistical methods for meta-analysis. *Stat Med* 2001; 20:825–40
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. *BMJ* 2003; 327:557–60
41. Lewis S, Clarke M: Forest plots: Trying to see the wood and the trees. *BMJ* 2001; 322:1479–80
42. Church J, Lodge D, Berry SC: Differential effects of dextromethorphan and levorphanol on the excitation of rat spinal neurons by amino acids. *Eur J Pharmacol* 1985; 111:185–90
43. Woolf CJ, Salter MW: Neuronal plasticity: Increasing the gain in pain. *Science* 2000; 288:1765–9
44. Woolf CJ, Thompson SW: The induction and maintenance of central sensitization is dependent on *N*-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. *Pain* 1991; 44:293–9
45. Woolf CJ, Chong MS: Preemptive analgesia—Treating postoperative pain by preventing the establishment of central sensitization. *Anesth Analg* 1993; 77:362–79
46. Dickenson AH: Spinal cord pharmacology of pain. *Br J Anaesth* 1995; 75:193–200
47. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB: High-dose oral dextromethorphan *versus* placebo in painful diabetic neuropathy and postherpetic neuralgia. *Neurology* 1997; 48:1212–8
48. Ben Abraham R, Marouani N, Kollender Y, Meller I, Weinbroum AA: Dextromethorphan for phantom pain attenuation in cancer amputees: A double-blind crossover trial involving three patients. *Clin J Pain* 2002; 18:282–5
49. Ben Abraham R, Marouani N, Weinbroum AA: Dextromethorphan mitigates phantom pain in cancer amputees. *Ann Surg Oncol* 2003; 10:268–74
50. Mercadante S, Casuccio A, Genovese G: Ineffectiveness of dextromethorphan in cancer pain. *J Pain Symptom Manage* 1998; 16:317–22
51. Katz NP: Morphidex (MS/DM) double-blind, multiple-dose studies in chronic pain patients. *J Pain Symptom Manage* 2000; 19(1 suppl):S37–41
52. Elia N, Tramèr MR: Ketamine and postoperative pain—A quantitative systematic review of randomised trials. *Pain* 2005; 113:61–70
53. Bem JL, Peck R: Dextromethorphan. An overview of safety issues. *Drug Saf* 1992; 7:190–9
54. Hinsberger A, Sharma V, Mazmanian D: Cognitive deterioration from long-term abuse of dextromethorphan: A case report. *J Psychiatry Neurosci* 1994; 19:375–7
55. Fleming PM: Dependence on dextromethorphan hydrobromide. *Br Med J (Clin Res Ed)* 1986; 293:597
56. Boyer EW: Dextromethorphan abuse. *Pediatr Emerg Care* 2004; 20:858–63
57. Schwartz RH: Adolescent abuse of dextromethorphan. *Clin Pediatr (Phila)* 2005; 44:565–8
58. Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. *Psychopharmacology (Berl)* 2012; 223:1–15
59. Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ: Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. *Drug Alcohol Depend* 2013; 128:206–13
60. Romanelli F, Smith KM: Dextromethorphan abuse: Clinical effects and management. *J Am Pharm Assoc (2003)* 2009; 49:e20–5; quiz e26–7
61. Oderda GM, Gan TJ, Johnson BH, Robinson SB: Effect of opioid-related adverse events on outcomes in selected surgical patients. *J Pain Palliat Care Pharmacother* 2013; 27:62–70
62. White PF, Kehlet H: Improving postoperative pain management: What are the unresolved issues? *ANESTHESIOLOGY* 2010; 112:220–5